Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M, Sarfati E, Moretti JL, Bouchard P, Toubert ME (2007). „Bone metastases of differentiated thyroid cancer: Impact of early 131I-based detection on outcome”. Endocrine-Related Cancer (Bioscientifica) 14 (3): 799–807. DOI:10.1677/ERC-07-0120. PMID17914109.
Hofman MS (2013). „Thyroid nodules: Time to stop over-reporting normal findings and update consensus guidelines”. BMJ347: f5742. DOI:10.1136/bmj.f5742. PMID24068719.
By 100% minus cause-specific mortality of 17% at 5 yr, as given by Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF (2005). „Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma”. Journal of Clinical Endocrinology & Metabolism90 (11): 6077–6084. DOI:10.1210/jc.2005-0044. PMID16091497.
Numbers from EUROCARE, from Page 10 in: F. Grünwald; Biersack, H. J.; Grںunwald, F. (2005). Thyroid cancer. Berlin: Springer. ISBN3-540-22309-6.
Numbers from National Cancer Database in the US, from Page 10 in: F. Grünwald; Biersack, H. J.; Grںunwald, F. (2005). Thyroid cancer. Berlin: Springer. ISBN3-540-22309-6. (Note:Book also states that the 14% 10-year survival for anaplastic thyroid cancer was overestimated)
medicinenet.com
„Thyroid Cancer”. MedicineNet.com. Pristupljeno 26 October 2011.
medscape.com
emedicine.medscape.com
Rounded up to nearest natural number from 96.7% as given by eMedicine Thyroid, Papillary Carcinoma Author: Luigi Santacroce. Coauthors: Silvia Gagliardi and Andrew Scott Kennedy. Updated: Sep 28, 2010
nih.gov
ncbi.nlm.nih.gov
Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M, Sarfati E, Moretti JL, Bouchard P, Toubert ME (2007). „Bone metastases of differentiated thyroid cancer: Impact of early 131I-based detection on outcome”. Endocrine-Related Cancer (Bioscientifica) 14 (3): 799–807. DOI:10.1677/ERC-07-0120. PMID17914109.
Hofman MS (2013). „Thyroid nodules: Time to stop over-reporting normal findings and update consensus guidelines”. BMJ347: f5742. DOI:10.1136/bmj.f5742. PMID24068719.
By 100% minus cause-specific mortality of 17% at 5 yr, as given by Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF (2005). „Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma”. Journal of Clinical Endocrinology & Metabolism90 (11): 6077–6084. DOI:10.1210/jc.2005-0044. PMID16091497.